Weight and blood pressure response to weight management and sibutramine in diabetic and non-diabetic high-risk patients: an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes (SCOUT) trial.

Abstract

OBJECTIVE:

To assess treatment responses to sibutramine and weight management in diabetic patients during the lead-in period of the Sibutramine Cardiovascular OUTcomes (SCOUT) trial.

METHODS:

SCOUT is an ongoing, prospective, randomized, double-blind, placebo-controlled outcome trial in cardiovascular high-risk overweight/obese patients. A total of 10 742 patients received single-blind sibutramine and individualized weight management during the 6-week lead-in period; 84% had a history of type 2 diabetes mellitus and additional co-morbidities. Post-hoc analyses assessed anthropomorphic and vital sign responses between patients with and without diabetes.

RESULTS:

Concomitant antidiabetic medication use was reported by 86% of the diabetic patients (approximately 30% required insulin-alone or in combination). Body weight and waist circumference decreased in diabetic patients: median 2.1 kg; 2.0 cm (both men and women); for those on insulin: 1.9 kg; 1.5/2.0 cm (men/women); without insulin: 2.3 kg; 2.0 cm (both men and women); blood pressure (BP) was also reduced (median systolic/diastolic 3.5/1.0 mmHg) with larger reductions in diabetic patients who were hypertensive and/or lost the most weight (>5%). In diabetic patients who entered with BP at target (<130/<85 mmHg) but did not lose weight (N = 245), increases of 3.5/2.0 mmHg were observed. Non-diabetic patients had greater weight losses (2.5 kg) but smaller reductions in BP (systolic/diastolic -2.5/-0.5 mmHg). Pulse rate increases were less in diabetic vs. non-diabetic patients (1.5 vs. 2.0 bpm).

CONCLUSION:

In these high-risk diabetic patients, sibutramine and lifestyle modifications for 6 weeks resulted in small, but clinically relevant, median reductions in body weight, waist circumference and BP. A small median increase in pulse rate was recorded.

• Authors: L F Van Gaal, I D Caterson, W Coutinho, N Finer, A P Maggioni, A M Sharma, C Torp-Pedersen, H Ge, S A Moran, G M Shepherd, W P T James, SCOUT Investigators
• Journal: Diabetes, obesity & metabolism (Diabetes Obes Metab) Vol. 12 Issue 1 Pg. 26-34 (Jan 2010) ISSN: 1463-1326 [Electronic] England
• PMID: 19758358 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Appetite Depressants
• Cyclobutanes
• sibutramine

Topics

• Aged
• Appetite Depressants (therapeutic use)
• Blood Pressure (drug effects)
• Cardiovascular Diseases (drug therapy, physiopathology, prevention & control)
• Cyclobutanes (therapeutic use)
• Diabetes Mellitus, Type 2 (complications, drug therapy, physiopathology)
• Diabetic Angiopathies (drug therapy, physiopathology, prevention & control)
• Double-Blind Method
• Female
• Humans
• Hypertension (drug therapy, etiology, physiopathology)
• Male
• Middle Aged
• Obesity (complications, drug therapy, physiopathology)
• Weight Loss (drug effects)